GileadSciences is pulling its blockbuster breast-cancer drug Trodelvy from use in certain patients with bladder cancer following the failure of a confirmatory study. Gilead on Friday said it ...
On Friday, GileadSciences (NASDAQ:GILD) maintained its Buy rating and $85.00 stock price target from TD Cowen, despite the pharmaceutical company's decision to voluntarily withdraw mUC indication ...